REG - Renalytix PLC - Half-year Report
Today 07:00
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260326:nRSZ1680Ya&default-theme=true
RNS Number : 1680Y Renalytix PLC 26 March 2026
Renalytix plc
("Renalytix" or the "Company")
Half Year Report
LONDON and NEW YORK, 26 March, 2026 - Renalytix plc (LSE: RENX) (OTCQB:
RNLXY), a precision medicine diagnostics company, whose
product kidneyintelX.dkd , is the only FDA-approved and Medicare-reimbursed
prognostic test to support early-stage risk assessment in chronic diabetic
kidney disease, announces its Half Year Report for the six months ended 31
December 2025 ("HY26").
Highlights include:
· Revenue growth to $1.6 million (H1 FY25: $1.3 million)
· 58 new practices sites added across four active regions of New York,
Texas, Florida and Arizona
· Expanded to five fully integrated EHR systems for seamless patient
identification, ordering and reporting, up from two in the prior year period
· Additional eight integrations initiated to expand access for
approximately 10,000 eligible patients
· Extended data integration pipelines to leading EMR platforms used in
primary care setting including Epic Systems, Athenahealth and eClinicalWorks
· Underlying EBITDA loss reduced year-on-year, reflecting disciplined
cost management
· Transition to new laboratory facility commenced to enhance capacity
and improve gross margin
· $9.5m raised through over-subscribed placing and retail offer at a
premium to prior 6 month share price
Post period end highlights include:
· Advancing contract discussion with major US diagnostic companies to
provide kidneyintelX.dkd with broad, national distribution and reduction in
logistics cost for blood sample transport
· Submission for publication of two year, multi-center Wake Forest
Atrium Health and Mount Sinai Health System outcomes data expected to support
further guidelines recommendations, expanded commercial insurance coverage and
doctor utility
· CE marking submission progressing, on target for completion of review
by end of FY26 and CE certification in Q1-FY27
· Advancement of program milestones for inclusion of kidneyintelX.dkd
in a major pharma drug trial in chronic kidney disease which, if successful,
is expected to significantly increase Company services revenue in CY 2026 and
beyond
For further information, please contact:
Renalytix plc www.renalytix.com
James McCullough, CEO Via Walbrook PR
SP Angel Corporate Finance LLP (Nominated Adviser, Joint Broker) Tel: +44 (0)20 3470 0470
Jeff Keating / David Hignell / Jen Clarke (Corporate Finance)
Vadim Alexandre (Corporate Broking)
Oberon Capital (Joint Broker) Tel: +44 (0)20 3179 5300
Mike Seabrook / Nick Lovering
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Alice Woodings Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654
About Renalytix ( www.renalytix.com )
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in
vitro diagnostics company, focused on optimizing clinical management of
kidney disease to drive improved patient outcomes. Renalytix has received FDA
approval and Medicare reimbursement for kidneyintelX.dkd which is now
offered commercially in the United States.
Unrecognized and uncontrolled diabetic kidney disease remains one of the
largest barriers to controlling cost and suffering in the United States and
the United Kingdom's medical system, affecting approximately 15 million and 8
million people, respectively. After five years of development and clinical
validation, kidneyintelX.dkd is the only FDA-approved and
Medicare-reimbursed prognostic tool capable of understanding a patient's risk
with diabetic kidney disease early where treatment has maximal
effect. kidneyintelX.dkd is now being deployed across large physician group
practices and health systems in select regions of the United States.
The over 15,000 patients that have been tested by kidneyintelX.dkd have
produced a substantial body of real-world performance data. In patient
populations where kidneyintelX.dkd has been deployed, a demonstrated and
significant increase in diagnosis, prognosis, and treatment rates have been
recorded. kidneyintelX.dkd now has full reimbursement established by
Medicare, the largest insurance payer in the United States, at $950 per
reportable result. kidneyintelX.dkd is also recommended for use in the
international chronic kidney disease clinical guidelines (KDIGO).
KidneyIntelX is based on technology developed by Mount Sinai faculty and
licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and
equity owners in the Company. In addition, the Icahn School of Medicine at
Mount Sinai has equity ownership in Renalytix. For information about the
kidneyintelX.dkd test, visit kidneyintelx.com.
Chief Executive Officer's Statement
The first half of FY26 has been a period of disciplined execution and
important structural progress for Renalytix as we continue to build the
commercial and operational foundations required to scale adoption of
kidneyintelX.dkd. Our priorities during the period were to expand clinical
adoption of kidneyintelX.dkd, advance integration-led deployment, strengthen
our clinical utility programme and enhance operational efficiency to support
scalable growth. I am pleased to report meaningful progress across each of
these areas.
Revenue Growth and Commercial Expansion
In February 2026, total revenues for the six months ended 31 December 2025
increased to $1.6 million compared to $1.3 million in the prior comparable
period. This growth reflects continued physician engagement and increasing
utilisation within integrated practices.
During the period we:
● Increased fully integrated EHR systems to five, compared to two in the prior
year period, supporting:
● The addition of 58 new practices; and
● The onboarding of over 135 new physicians
We also initiated our largest contracted integration pipeline to date, with
eight integrations progressing through deployment, expected to provide access
to approximately 10,000 eligible patients upon completion.
The majority of patients in commercial testing continued to be conducted and
collected at the established rate of $950.
Also, as previously reported, integration capability was successfully deployed
across multiple leading U.S. EMR platforms, including Epic Systems,
athenahealth and eClinicalWorks. This multi-platform capability materially
broadens our addressable market and establishes a scalable, repeatable
deployment model across diverse healthcare systems, reducing technical
barriers to future expansion. This integration-led approach embeds
kidneyintelX.dkd directly within clinical workflows, supporting consistent
utilisation and creating a scalable pathway for long-term revenue growth.
We expect to publish our two-year outcomes study by the end of H2 FY26,
providing further validation of the impact of kidneyintelX.dkd in accurately
identifying patient risk, driving adoption of Guideline Directed Medical
Therapies and leading to measurement improvements in Cardiovascular, Kidney
and Metabolic health. This data builds upon the growing evidence base for
kidneyintelX.dkd including three data presentations at the American Society
for Nephrology Kidney Week conference. Continued evidence generation remains
central to long-term adoption, payer engagement and system-level integration.
In parallel, we are progressing submission of our application for CE marking,
supporting potential international expansion and supporting emerging pharma
opportunities.
Update on Full-Year Revenue Expectations
We continue to advance contracting discussions with large strategic concerns
to expand distribution of kidneyintelX.dkd to all US state territories.
Management believes that national distribution, in concert with one or more
major diagnostic and/or laboratory concerns, will result in significant uptake
of kidneyintelX.dkd across the estimated 10 million US patients with full
insurance coverage for kidneyintelX.dkd and a broader group that can access
kidneyintelX.dkd early prognostic testing through commercial insurance or
concierge medicine.
A national testing distribution agreement would include an economic share of
kidneyintelX.dkd testing services revenue in exchange for joint-marketing,
access to a sales force with national exposure, use of existing infrastructure
for blood draw and transport, and joint-education and support.
Management believes it is in the best interest of shareholders to conclude a
national distribution agreement in calendar year 2026, to ensure access to the
entire kidneyintelX.dkd eligible testing patient population without a
requirement for significant capital expenditure on commercial infrastructure,
sales force build and marketing.
As announced in the H1 trading update, we now expect full-year revenue to be
c.$4m. This primarily reflects the timing and complexity of EMR integrations
and workflow activation within healthcare systems, but does not reflect
reduced demand or weakening clinical engagement. While our integration-led
strategy builds durable and scalable utilisation, implementation
cycles-particularly within larger, multi-site organisations-can extend beyond
initial projections. We continue to develop our distribution opportunities,
including leveraging partnerships with MVP Health and Tempus AI, focused on
driving commercial traction and advancing testing of kidneyintelX.dkd.
We anticipate revenue acceleration in the second half of FY26 as recent
integrations mature, coupled with increased distribution driving and improved
momentum into FY27.
Operational Discipline and Margin Improvement
Alongside commercial expansion, we have maintained strict financial
discipline. Underlying EBITDA loss improved compared to the prior year period,
reflecting careful management of operating expenses and targeted allocation of
resources.
Cash management remains a core priority. We continue to align expenditure with
commercial deployment milestones and infrastructure development, ensuring that
investment supports scalable growth while maintaining operational prudence.
During the period, we advanced the transition to our new laboratory facility.
The new laboratory is designed to:
● Increase operational capacity to support materially higher testing volumes
● Improve gross margin through a more efficient fixed cost structure
● Reduce fixed costs per test as utilisation scales
● Enhance long-term operating leverage
This enhanced infrastructure strengthens our ability to translate future
revenue growth more effectively into margin expansion.
Positioning for the Next Phase
The progress delivered in H1 FY26 strengthens the structural foundations of
the Company. We have expanded our integrated clinical network, advanced
validation milestones, enhanced operational efficiency and maintained
financial discipline.
These achievements position Renalytix for the next phase of scaled growth as
integrations convert, utilisation builds and operating leverage improves. We
look forward to providing our shareholders with a further update in due course
as they progress.
I would like to thank our employees, partners, clinicians and shareholders for
their continued support as we execute our mission to improve risk
stratification and outcomes for patients with kidney disease.
James McCullough
Chief Executive Officer
Financial Review
The results presented cover the six months ended 31 December 2025 ("HY26").
The presentational currency for Renalytix plc and its subsidiaries (together,
the "Group") is the United States Dollar.
INCOME STATEMENT
Revenue
The Group recognised $1.6 million in total revenue for HY26 (HY25: $1.3
million). Life sciences revenues increased during the period, reflecting
ongoing research and clinical study-related testing activities, with
$0.5 million recognised (HY25: $0.1 million).
Commercial test revenues were $1.1 million (HY25: $1.2 million). The
year-on-year reduction primarily reflects the timing of EMR integrations and
clinical workflow activation within healthcare systems as the Company
continues its transition to an integration-led commercial model following
Medicare coverage.
The Group's commercial test revenues remain sensitive to insurance
reimbursement coverage and the timing of payment from Medicare and Medicare
Advantage plans. KidneyIntelX billed testing to Medicare and Medicare
Advantage continues to achieve greater than 95% payment on submitted claims,
demonstrating strong reimbursement reliability once testing is embedded within
routine clinical practice.
Cost of Sales
The cost of sales associated with the revenue was $0.8 million for
HY26 (HY25: $0.8 million). The transition to the new laboratory facility
during the period is expected to support improved operational efficiency and
gross margin as testing volumes scale.
Administrative Costs
Continued cost reduction across the business led to lower administrative
costs of $7.9 million in HY26 (HY25: $8.0 million), a reduction of
$0.1 million for the period.
The major items of expenditure were general and administrative costs which
included $4.4 million in employee related costs (HY25: $4.3 million),
$0.6 million in subcontractors, legal, accounting, and other professional
fees (HY25: $1.6 million), $0.6 million in external R&D Services, lab
supplies and lab services (HY25: $0.3 million), $0.6 million in stock
based compensation (HY25 $0.3 million), $0.6 million in marketing and
public relations (HY25: $0.2 million), $0.5 million in IT related costs
(HY25: $0.4 million), $0.2 million in insurance (HY25: $0.4 million), $0.2
million in office related expenses including rent (HY25 $0.2 million),
$0.1 million in stock exchange listing and filing fees (HY25: $0.2 million),
$0.03 million in depreciation and amortisation (HY25: $0.03 million), and
$0.04 million in other miscellaneous expenses (HY25: $0.1 million). We
anticipate further expense reductions to occur throughout the remainder of
FY26.
Underlying EBITDA
UNAUDITED UNAUDITED AUDITED
Period to Period to Year to
31 December 2025 31 December 2024 30 June 2025
$M $M $M
Operating Loss (7.1) (7.5) (17.2)
Share-based payments 0.6 0.3 3.2
Severance payments 0.1 - -
Depreciation & Amortisation 0.0 0.0 0.0
Underlying EBITDA (6.4) (7.2) (14.0)
The Group presents underlying EBITDA as a supplemental performance measure to
provide investors with additional insight into the underlying operating
performance of the business. Underlying EBITDA is defined as operating loss
before share-based payments, severance costs, depreciation and amortisation,
and other non-recurring items. The Directors believe this measure assists in
understanding the underlying cost structure of the Group and provides a useful
basis for comparing operating performance between periods.
Underlying EBITDA loss for the period was $6.4 million, compared with $7.2
million in HY25, reflecting improved cost discipline across the business
despite the timing impact on revenues during the period.
The Group reported an operating loss of $7.1 million for HY26 (HY25: $7.5
million). Adjustments to arrive at underlying EBITDA included $0.6 million of
share-based payments, $0.1 million of severance costs, together with
immaterial depreciation and amortisation.
The improvement in underlying EBITDA compared to the prior period reflects
continued management focus on controlling operating expenses while maintaining
investment in commercial deployment, integration capabilities and clinical
validation activities.
The Group remains focused on managing its cost base carefully while
positioning the business to benefit from increased utilisation as EMR
integrations convert and testing volumes scale.
Gain (Loss) On Financial Assets At Fair Value Through Profit Or Loss
The Group accounts for the investment in VericiDx equity securities at fair
value, with changes in fair value recognised in the income statement. During
HY26, we recorded a loss of $0.04 million to adjust the VericiDx investment
to fair value. During HY25, we recorded a loss of $0.2 million to adjust the
VericiDx investment to fair value.
Fair Value Adjustment Of Convertible Debt
The convertible bonds are accounted for as a host debt contract with an
embedded derivative. The embedded derivative is measured at fair value, with
changes in fair value recognised in the income statement. During HY26 a $0.3m
fair value gain was recognised in the income statement relating to the
embedded derivative component of the convertible bonds.
Finance Income (Expense)
During HY26, we recognised a loss of $0.7 million
(HY25: $0.5 million loss), which was comprised of $0.02 million interest
income earned on our cash deposits (HY25: $0.01 million), $0.04 of grant
income (HY25: $0.04 million), $0.4 million of foreign exchange losses (HY25:
$0.5 million loss), and $0.4 of interest expense (HY25: $0.1 million).
BALANCE SHEET
Inventory
Inventory consists of consumable materials used by the labs to carry out
KidneyIntelX. Inventory on hand at 31 December 2025 totaled $0.3 million
(FY25: $0.2 million).
Fixed Assets
Property, plant, and equipment consists of laboratory equipment being used to
support testing and product development activities. The right of use asset
("RoU") relates to lease for the new laboratory. At 31 December 2025, the
company held $1.3 million in net property, plant, and equipment including RoU
assets (FY25: $0.2 million).
Intangible Assets
The Group held no intangible assets as at 31 December 2025 (FY25: Nil).
Investment in Verici
At the end of HY26, the group held 8,581,682 shares in Verici Dx, the fair
value of the investment in Verici Dx was $0.1 million at 31 December
2025(FY25: $0.1 million).
Convertible Note
The Company has a convertible bond, issued in November 2024 for $7.8 million
with a maturity date of July 2029. Interest accrues on a quarterly basis and
may be settled or rolled into the Bond on a payment in kind ("PIK") election.
The bond contains a conversion feature allowing the bond to be converted to
shares during the Bond period. This conversion feature meets the definition of
an embedded derivative. The debt component is recognised on an effective
interest basis and the equity component is accounted for at fair value at the
reporting date with changes in fair value recognised in the income statement.
Changes in fair value of the embedded derivatives recognised in the income
statement at H1 FY26 were ($0.3 million) (HY25: nil). During the period $4.0m
of the bond principal along with accrued interest was converted by the bond
holder into equity. This was settled through issuing of 31,650,034 ordinary
shares. Following the conversion the value of the host contract was reduced by
$3.5m and the derivative liability by $0.8m. The value of the debt host
contract at 31 December 2025 was $3.8 million and the value of the embedded
derivative was $0.5 million.
Cash
At 31 December 2025, the Group had cash and cash equivalents of $6.1 million
(FY25: $3.6 million). The Group currently holds cash and cash equivalents of
$3.4 million. The Group's cash is held in multiple short term deposit
accounts.
FINANCIAL STATEMENTS
Unaudited Consolidated Income Statement
FOR THE PERIOD ENDED 31 December 2025
Notes UNAUDITED UNAUDITED AUDITED
Period to Period to Year to
31 December 2025 31 December 2024 30 June 2025
$M $M $M
Continuing Operations
Revenue 6 1.6 1.3 3.0
Cost of Sales 7 (0.8 ) (0.8 ) (1.8 )
Gross profit 0.8 0.5 1.2
Administrative expenses 8 (7.9 ) (8.0 ) (18.4 )
Operating loss (7.1 ) (7.5 ) (17.2 )
Impairment of Intangibles - - 0.0
Gain (loss) on financial assets at fair value through profit or loss (0.0 ) (0.2 ) (0.6 )
Fair value adjustment of convertible debt 11 (0.3 ) (0.4 ) (0.4 )
Settlement of convertible bond 11 - - (3.5 )
Finance (costs) income - net (0.7 ) (0.5 ) (0.1 )
Loss before tax (8.1 ) (8.6 ) (21.8 )
Taxation - - 1.4
Loss for the Period (8.1 ) (8.6 ) (20.4 )
Earnings per Ordinary share from continuing operations
Basic 9 $ (0.02 ) $ (0.05 ) $ (0.07 )
Diluted 9 $ (0.02 ) $ (0.05 ) $ (0.07 )
Unaudited Consolidated Statement of Comprehensive Income
FOR THE PERIOD ENDED 31 December 2025
UNAUDITED UNAUDITED AUDITED
Period to Period to Year to
31 December 2025 31 December 2024 30 June 2025
$M $M $M
Loss for the period - continuing operations (8.1 ) (8.6 ) (20.4 )
Other comprehensive income:
Items that may be subsequently reclassified to profit or loss
Changes in the fair value of the convertible notes - (0.1 ) -
Settlement of convertible notes - (0.3 ) -
Currency translation differences 0.3 (0.3 ) (0.9 )
Other comprehensive (loss)/income for the period 0.3 (0.7 ) (0.9 )
Total comprehensive loss for the period (7.8 ) (9.3 ) (21.3 )
Unaudited Consolidated Statements of Financial Position
AS AT 31 December 2025
Notes UNAUDITED UNAUDITED AUDITED
As at As at As at
31 December 2025 At 31 December 2024 30 June 2025
$M $M $M
Assets
Non-current assets:
Property, plant and equipment 0.2 0.2 0.2
Right of use asset 1.1 - -
Other long term assets 0.1 0.1 0.1
Total non-current assets 1.4 0.3 0.3
Current Assets
Inventory 0.3 0.4 0.2
Security Deposits 0.1 0.1 0.1
Financial asset at fair value through profit or loss 0.1 0.4 0.1
Trade and other receivables 1.3 0.5 0.6
Prepaid and other current assets 0.6 0.6 1.2
Cash and cash equivalents 6.1 9.2 3.6
Total current assets 8.5 11.2 5.8
Total assets 9.9 11.4 6.1
Equity attributable to owners of the parent
Share capital 10 1.4 1.1 1.1
Share premium 10 154.2 137.9 141.3
Share-based payment reserve 18.3 14.8 17.7
Accumulated other comprehensive income (1.7 ) (1.8 ) (2.0 )
Retained earnings/(deficit) (173.4 ) (153.3 ) (165.1 )
Total equity (1.2 ) (1.4 ) (7.0 )
Liabilities
Current liabilities:
Trade and other payables 5.3 4.6 4.8
Current lease liabilities 0.2 - -
Total current liabilities 5.4 4.6 4.8
Non-current liabilities
Note payable non-current 11 4.7 8.2 8.3
Non-current lease liabilities 0.9 - -
Total non-current liabilities 5.6 8.2 8.3
Total liabilities 11.0 12.8 13.1
Total equity and liabilities 9.9 11.4 6.1
Unaudited Consolidated Statements of Cash Flows
FOR THE PERIOD ENDED 31 December 2025
Notes UNAUDITED UNAUDITED AUDITED
Period to Period to Year to
31 December 2025 31 December 2024 30 June 2025
$'000 $'000 $'000
Cash flows from operating activities:
Loss before income tax (8.1 ) (8.6 ) (21.8 )
Adjustments for
Depreciation 0.0 0.0 0.0
Share-based payments 0.6 0.3 3.2
Cost of repayment of convertible bond 11 - - 3.5
Unrealized loss (gain) on financial asset at fair value through profit or loss 0.0 0.2 0.5
Realized loss on sale of ordinary shares in VericiDx - 0.0 0.0
Fair value adjustment of convertible debt 11 0.3 0.4 0.4
Foreign exchange gain 0.4 0.4 (0.4 )
Changes in working capital
Trade and other receivables (0.6 ) 0.2 0.1
Prepaid assets and other current assets 1.7 (0.6 ) (0.8 )
Inventory (0.2 ) (0.1 ) 0.1
Trade and other payables 0.5 (2.5 ) (2.7 )
Net cash used in operating activities (5.4 ) (10.3 ) (17.9 )
Cash flows from investing activities:
Purchase of property and equipment (0.1 ) - -
Proceeds from sale of investments - 0.0 0.0
Net cash generated by/(used in) investing activities (0.1 ) 0.0 0.0
Cash flows from financing activities
Repayment of convertible notes 11 (4.2 ) (3.5 ) (3.5 )
Issue of shares (net of issue costs) 10 12.8 18.5 19.5
Lease payments (0.0 ) - -
Net cash generated from financing activities 8.6 15.0 16.0
Net increase/(decrease) in cash and cash equivalents 3.1 4.7 (1.9 )
Cash and cash equivalents at beginning of period 3.6 4.7 4.7
Effect of exchange rate changes on cash (0.6 ) (0.2 ) 0.8
Cash and cash equivalents at end of period 6.1 9.2 3.6
Unaudited Consolidated Statement of Changes in Equity
FOR THE PERIOD ENDED 31 December 2025
Share-based payment Accumulated other comprehensive Retained
Share Capital Share Premium reserve income earnings Total Equity
$M $M $M $M $M $M
At 30 June 2024 and 1 July 2024 0.5 121.8 14.5 (1.1 ) (144.7 ) (9.0 )
Comprehensive income
Loss for the period - - - - (8.6 ) (8.6 )
Other comprehensive income
Changes in fair value of convertible notes - - - (0.1 ) - (0.1 )
Settlement of convertible notes - - - (0.3 ) - (0.3 )
Currency translation differences - - - (0.3 ) - (0.3 )
Total comprehensive income - - - (0.7 ) (8.6 ) (9.3 )
Transactions with Owners
Share-based payments - - 0.3 - - 0.3
Shares issued for repayment of convertible bond 0.0 1.6 - - - 1.6
Shares capital issued 0.5 18.0 - - - 18.5
Cost of repayment of convertible bond - (3.5 ) - - - (3.5 )
Total transactions with owners of the parent, recognized directly in equity 0.6 16.1 0.3 - - 16.9
At 31 December 2024 and 1 January 2025 1.1 137.9 14.8 (1.8 ) (153.3 ) (1.4 )
Comprehensive income
Loss for the period (11.8 ) (11.8 )
Other comprehensive income
Currency translation differences (0.2 ) (0.2 )
Total comprehensive income - - - (0.2 ) (11.8 ) (12.0 )
Transactions with Owners
Share-based payments - - 2.9 2.9
Cost of repayment of convertible bond 3.5 3.5
Total transactions with owners of the parent, recognized directly in equity - 3.5 2.9 (0.2 ) (11.8 ) (5.7 )
At 30 June 2025 and 1 July 2025 1.1 141.3 17.7 (2.0 ) (165.1 ) (7.0 )
Comprehensive income
Loss for the period - - - - (8.3 ) (8.3 )
Other comprehensive income
Currency translation differences - - 0.3 - 0.3
Total comprehensive income - - - 0.3 (8.3 ) (8.0 )
Transactions with Owners
Share-based payments - - 0.6 - - 0.6
Shares capital issued 0.3 9.2 - - - 9.5
Less Issue Costs - (0.6 ) (0.6 )
Shares issued for conversion of convertible bond 0.1 4.2 4.3
Total transactions with owners of the parent, recognized directly in equity 0.4 12.8 0.6 - - 13.8
At 31 December 2025 1.4 154.2 18.3 (1.7 ) (173.4 ) (1.2 )
Notes to the Financial Statements
1. GENERAL INFORMATION AND BASIS OF PRESENTATION
Renalytix Plc (the "Company") is a company incorporated in the United Kingdom.
The Company is a public limited company, which is listed on the AIM market of
the London Stock Exchange and OTCQB market. The address of the registered
office is 2 Leman Street, London, United Kingdom, E1W 9US. The Company was
incorporated on 15 March 2018 and its registered number is 11257655
The principal activity of the Company and its subsidiaries (together "the
Group") is as a developer of artificial intelligence- enabled diagnostics for
kidney disease.
The financial statements are presented in United States Dollars ("USD")
because that is the currency of the primary economic environment in which the
Group operates.
2. BASIS OF PRESENTATION
This interim financial report, which is unaudited, does not constitute
statutory accounts within the meaning of section 434(3) of the Companies Act
2006. These interim financial statements have been prepared in accordance with
the AIM rules and IAS 34.
The accounts of Renalytix plc for the period ended 30 June 2025, which were
prepared in accordance with international accounting standards in conformity
with the requirements of the Companies Act 2006 ("UK-adopted international
accounting standards"), have been delivered to the Registrar of Companies.
Those accounts were prepared and audited as required by the Companies Act
2006.
The financial statements are presented in United States Dollars ("USD")
because that is the currency of the primary economic environment in which the
Group operates. This interim financial report for the six-month period ended
31 December 2025 (including comparatives for the six months ended 31 December
2024 and 12 months to 30 June 2025) was approved by the Board of Directors on
26 March 2026.
New standards, amendments, and interpretations not adopted by the group
The group did not adopt any new standards, amendments or interpretations in
year as they did not have a material impact on the financial statements.
New standards, amendments, and interpretations issued but not effective for
the period ended 31 December 2025, and not early adopted
A number of new standards and amendments to standards and interpretations are
effective for annual periods beginning on or after 1 January 2025 and have
not been applied in preparing these financial statements. None of these is
expected to have a significant effect on the financial statements of the
Group.
Amendments to IAS 21 -- Lack of Exchangeability (effective for annual periods
beginning on or after 1 January 2025).
Amendments to the Classification and Measurement of Financial Instruments -
Amendments to IFRS 9 and IFRS 7 (effective for annual periods beginning on or
after 1 January 2026).
IFRS 19 Subsidiaries without Public Accountability: Disclosures (effective for
annual periods beginning on or after 1 January 2027) Amendments to IAS 12:
Deferred Tax Related to Assets and Liabilities Arising From a Single
Transaction.
IFRS 18 Presentation and Disclosure in Financial Statements (effective for
annual periods beginning on or after 1 January 2027) Amendments to IAS 7 and
IFRS 7: Supplier Finance Arrangement.
3. SIGNIFICANT ACCOUNTING POLICIES
The principal accounting policies applied in the preparation of these
financial statements are set out below.
Going concern
The Group and Company meet their day-to-day working capital requirements
through the use of cash reserves.
The Directors have considered the applicability of the going concern basis in
the preparation of these financial statements.
Following an over subscribed fundraise in September 2025 we have strengthened
our cash position and we are in a net current asset position as at 31 December
2025.
The Group continues to advance its commercial strategy, including the
implementation of KidneyIntelX within healthcare systems, which is expected to
support increased test volumes over time. However, the timing of revenue
growth is dependent on the pace of healthcare system integrations and clinical
workflow activation.
The Directors are aware that as opportunities arise, working capital
restraints may mean the Group needs to seek additional funding through public
or private equity offerings, debt financings, other collaborations, strategic
alliances and licensing arrangement in order to ensure it can support growth
potential and capitalise on current and new opportunities within the market.
The current cost base of the Group has been established to support future
revenue growth from increased test volumes and life sciences activities. The
Directors believe that elements of the Group's cost base could be reduced if
required, in order to extend the Group's cash runway should revenue growth
occur more slowly than anticipated. Despite these mitigating factors, the
Group's business model relies on continued revenue growth and access to
additional funding to support its longer-term development. The Directors
therefore recognise that there exists a material uncertainty which may cast
significant doubt on the Group's ability to continue as a going concern.
The consolidated financial statements do not include any adjustments that may
result from the outcome of this going concern uncertainty.
Accounting policies
The same accounting policies, presentation and methods of computation have
been followed in these condensed interim financial statements as were applied
in the preparation of the company's annual financial statements for the year
ended 30 June 2025.
4. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS
The Company makes estimates and assumptions regarding the future. Estimates
and judgments are continually evaluated based on historical experience and
other factors, including expectations of future events that are believed to be
reasonable under the circumstances. In the future, actual results may differ
from these estimates and assumptions. The estimates and assumptions that have
a significant risk of causing a material adjustment to the carrying amounts of
assets and liabilities within the next financial year relate to:
● Convertible debt recorded at fair value through profit or loss (note 11).
● Share based payments.
5. SEGMENTAL REPORTING
Operating segments are reported in a manner consistent with the internal
reporting provided to the chief operating decision maker. The chief operating
decision-maker, who is responsible for allocating resources and assessing
performance of the operating segments, has been identified as the Executive
Directors who make strategic decisions. At present the Directors consider the
business to operate in a single segment.
6. REVENUE
Testing services revenue
Testing services revenue is generated from the KidneyIntelX platform, which
provides analytical services to customers. Each individual test is a
performance obligation that is satisfied at a point in time upon completion of
the testing process (when results are reported) which is when control passes
to the customer and revenue is recognized. During the period ended 31 December
2025, the Company recognized $1.1 million of testing services revenue. Sales
tax and other similar taxes are excluded from revenues. There was
$1.2 million of testing services revenue recognized in the period ended 31
December 2024.
Life sciences revenue
Life sciences revenue is generated from the provision of analytical services
to customers. Contracts with customers generally include an initial upfront
payment and additional payments upon achieving performance milestones. The
Company uses present right to payment and customer acceptance as indicators to
determine the transfer of control to the customer which may occur at a point
in time or over time depending on the individual contract terms. Sales tax and
other similar taxes are excluded from revenues. During the period ended 31
December 2025, there was $0.5 million of life sciences revenues recognised.
There was $0.1 million of life sciences revenue recognized in the period
ended 31 December 2024.
7. COST OF SALES - ANALYSIS BY NATURE
UNAUDITED UNAUDITED AUDITED
Period to Period to Year to
31 December 2025 31 December 2024 30 June 2025
$M $M $M
Direct Labour 0.2 0.2 0.5
Rent 0.2 0.2 0.4
Freight & Sample Collection 0.2 0.2 0.5
Depreciation & Amortisation 0.0 - -
Inventory Movements 0.1 0.1 0.3
Royalties 0.1 0.1 0.1
Total Cost of Sales 0.8 0.8 1.8
8. EXPENSES - ANALYSIS BY NATURE
UNAUDITED UNAUDITED AUDITED
Period to Period to Year to
31 December 2025 31 December 2024 30 June 2025
$'000 $'000 $'000
Employee - related 4.4 4.3 9.0
Subcontractors, legal, accounting, & other professional fees 0.6 1.6 2.4
External R&D services, lab supplies, and lab services 0.6 0.3 0.9
Insurance 0.2 0.4 0.7
Depreciation & Amortisation 0.0 0.0 0.0
Marketing & PR 0.6 0.2 0.4
IT costs 0.5 0.4 0.9
Office related (including rent) 0.2 0.2 0.3
Stock exchange listing & filing fees 0.1 0.2 0.2
Other expenses 0.0 0.1 0.4
Stock based compensation 0.6 0.3 3.2
Total administration expenses 7.9 8.0 18.4
9. EARNINGS PER SHARE
Basic net loss per ordinary share is computed by dividing net loss by the
weighted average number of ordinary shares outstanding during each period.
Diluted net loss per ordinary share includes the effect, if any, from the
potential exercise or conversion of securities, such as options which would
result in the issuance of incremental ordinary shares. Potentially dilutive
securities outstanding as of 31 December 2025, have been excluded from the
computation of diluted weighted average shares outstanding as they would be
anti-dilutive. Therefore, the weighted average number of shares used to
calculate both basic and diluted net loss per share are the same.
UNAUDITED UNAUDITED AUDITED
Period to Period to Year to
31 December 2025 31 December 2024 30 June 2025
Loss attributable to owners of the parent (in millions) $ (8.1 ) $ (8.6 ) $ (20.4 )
Weighted average number of ordinary shares in issue 382,510,307 159,527,895 274,579,701
Basic loss per share $ (0.02 ) $ (0.05 ) $ (0.07 )
The Company was incorporated on 15 March 2018 with 50,000 ordinary shares of
£1.00 each, and as a result of subdivisions (100:1 on 4 May 2018 and then 4:1
on 24 October 2018), the resulting founding shares became 20,000,000 at
£0.0025 each.
10. SHARE CAPITAL
Total Number of Ordinary Shares Share Premium Total
Group and Company Movement Shares $'000 $'000 $'000
At 30 June 2023 93,781,478 299 104,952 105,251
17-Jul-23 Shares issued for repayment of convertible bond 1,052,422 94,833,900 3 1,673 1,676
4-Aug-23 Vesting of RSUs 185,540 95,019,440 1 138 139
6-Oct-23 Shares issues under ESPP 75,328 95,094,768 - 93 93
19-Oct-23 Shares issued for repayment of convertible bond 2,335,388 97,430,156 7 1,338 1,345
15-Dec-23 Shares issued for repayment of convertible bond 2,500,000 99,930,156 8 523 531
At 31 December 2023 99,930,156 318 108,717 109,035
14-Mar-24 Shares issued under the Securities Purchase Agreement 19,986,031 119,916,187 63 3,964 4,027
10-Apr-24 Shares issued for repayment of convertible bond 3,636,162 123,552,349 11 1,442 1,454
16-Apr-24 Shares issued under the Securities Purchase Agreement 2,666,667 126,219,016 8 989 998
22-Apr-24 Shares issued under the Securities Purchase Agreement 1,333,334 127,552,350 4 498 502
24-Apr-24 Shares issued under the Securities Purchase Agreement 26,815,841 154,368,191 85 6,203 6,288
At 30 June 2024 154,368,191 491 121,813 122,304
17-Jul-24 Shares issued for repayment of convertible bond 11,557,322 165,925,513 37 1,551 1,588
9-Oct-24 Shares capital issued 24,007,773 189,933,286 78 2,515 2,594
6-Nov-24 Shares capital issued 141,272,726 331,206,012 457 15,461 15,918
At 31 December 2024 331,206,012 1,063 141,340 142,403
At 30 June 2025 331,206,012 1,063 141,340 142,403
29-Sep-25 Shares capital issued 74,162,634 405,368,646 249 8,606 8,856
15-Oct-25 Shares issued for conversion of convertible bond 31,650,034 437,018,680 106 4,223 4,330
At 31 December 2025 437,018,680 1,419 154,170 155,588
Ordinary Shares have a par value of £0.0025 each. All issued shares are fully
paid.
11. CONVERTIBLE DEBT
The amortising senior bonds with a due date in April 2027 ("old bond") were
settled during the prior period and replaced with a new non amortising
convertible bond with a due date in July 2029 ("new bond"). The new bond was
issued in November 2024 and has a maturity date of July 2029. There are no
capital repayments during the term with the full bond and any unpaid or
accrued interest due at the maturity date. Interest is payable in cash at 5.5%
of the bond on a quarterly basis, or the Group can elect to pay 7.5% on a
Payment in Kind ("PIK") basis where the interest is added to the bond at the
end of each quarter. The bond holder has a right to convert the bonds into
shares at a price of $0.30 per share during the conversion period which starts
on 1 April 2026, or in the event of a further capital raise, when the
conversion amount shall be equal to the price set for such capital raise. The
bond issuer has a cash alternative election where by they can settle the
amount of shares due upon conversion by the bond holder in cash. The cash
price due is calculated by the weighted average share price in the 10 days
prior to the election made by the bond holder. The bond holder has the right
to redeem the bonds in their entirety at any time during the term at the
Optional Redemption Price which is the greater of the principal amount of the
bonds including unpaid interest or the relevant parity value of the bonds.
In October 2025, the bond holder elected its right to convert part of the bond
for equity following the fund raise completed in September 2025. $4m of the
principal bond and the outstanding interest for the quarter at 5.5% were
converted into equity at a price of 9.5 pence per share. This was settled
through the issuance of 31,650,034 ordinary shares. The total amount converted
represented 48.8% of the total principal on the date of conversion. In
accordance with accounting standards the fair value of the derivative was
calculated immediately before the conversion of the bond to $1.7m. The host
debt contract was reduced by 48.8% to $3.7m and the derivative liability
reduced by 48.8% to $0.9m following the conversion of the bond.
The convertible debt and redemption option are considered to be an embedded
derivative and in accordance with the applicable accounting standards must be
recognised separately from the host debt contract at fair value. The embedded
derivative is accounted for through fair value to profit or loss and is
revalued at each reporting date. The derivative was revalued using a Black
Scholes model to determine the fair value of the underlying option. The
variables used in determining the calculation included the risk free rate of
4.47% and share price volatility of 69%. The risk free rate was determined
using UK government gilts and the share volatility was determined based on the
historic closing share price for the Company, both of which are considered to
be observable inputs in the fair value hierarchy. As we have used a valuation
model using observable inputs the valuation would fall under level 2 in the
fair value hierarchy set out in IFRS 13. During the period ended 31
December 2025, changes recognised for the fair value of the embedded
derivative were $0.3 million. Interest of $0.4 million has been accrued on a
PIK basis during the period.
UNAUDITED UNAUDITED AUDITED
As at As at As at
31 December 2025 31 December 2024 30 June 2025
$M $M $M
Beginning of Period 8.3 8.5 8.5
Fair value adjustments(1) 0.8 0.8
Change due to payment of principal and interest(2) - (1.2) (1.2)
Change in credit risk(3) - 0.1 0.1
FX Impact (0.0) 0.1
Subtotal 8.3 8.1 8.2
Derecognise Old Bond(4) - (8.1) (8.2)
New Loans:
New Bond Recognition(5) - 6.3 6.4
Derivative Liability(6) - 1.5 1.5
Loan7 - 0.3 0.3
Accrued Interest(8) 0.4 0.1 0.5
Fair Value Adjustment of Derivative Liability(9) 0.3 - (0.4)
Bond Conversion(10) (4.3) - -
End of Period 4.7 8.2 8.3
1. Fair value adjustments related to non-instrument specific credit risk
recognized as a loss in the consolidated statement of comprehensive income.
2. In July 2024, the Company made an amortisation payment of $1,243,900, which
consisted of $1,060,000 in principal and $174,900 in interest, through the
issuance of 2,275,000 Ordinary Shares and 4,641,161 American Depositary
Shares ("ADSs").
3. Increase in fair value of the notes related to instrument-specific risk
recognised as comprehensive loss.
4. The new bond was formally issued in November 2024 and replaced the old bond.
The old bond was derecognised with a gain recognised in the consolidated
statement of comprehensive income upon derecognition.
5. The host liability was recorded on the balance sheet at $6.3 million using
the effective interest rate method.
6. The convertible element of the bond was considered to be an embedded
derivative. The fair value of the derivative at inception was at $1.5
million
7. $325,000 of debt that was due to a professional adviser was restructured as a
long-term promissory note, bearing paid-in-kind interest at 5% per annum.
8. Interest of $0.4 million was accrued on a PIK basis during the period related
to the convertible loan and the non-convertible loan referenced in note 7
above,
9. Management used the Black-Scholes model to value the embedded derivative.
Using the model, the fair value increase of $0.3 million was recognised as a
loss in the consolidated income statement.
10. Reduction in value of the embedded derivative and host contract liability by
the proportion of principal loan converted.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IR EAFDSAFSKEAA
Copyright 2019 Regulatory News Service, all rights reservedRecent news on Renalytix
See all newsREG - Renalytix PLC - Half-year Report
AnnouncementREG - Renalytix PLC - Holding(s) in Company
AnnouncementREG - Renalytix PLC - Holding(s) in Company
AnnouncementREG - Renalytix PLC - Holding(s) in Company
AnnouncementREG - Renalytix PLC - Holding(s) in Company
Announcement